These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2351565)

  • 61. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ADCC of cultured human melanoma cells: analysis with monoclonal antibodies to human melanoma-associated antigens.
    Imai K; Ng AK; Glassy MC; Ferrone S
    Scand J Immunol; 1981 Oct; 14(4):369-77. PubMed ID: 7336169
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins.
    Mortarini R; Gismondi A; Maggioni A; Santoni A; Herlyn M; Anichini A
    Cancer Res; 1995 Oct; 55(20):4702-10. PubMed ID: 7553652
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies.
    Imai K; Ng AK; Glassy MC; Ferrone S
    J Immunol; 1981 Aug; 127(2):505-9. PubMed ID: 6166672
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro differentiation of human melanoma cells analyzed with monoclonal antibodies.
    Ziegler-Heitbrock HW; Munker R; Johnson J; Petersmann I; Schmoeckel C; Riethmüller G
    Cancer Res; 1985 Mar; 45(3):1344-50. PubMed ID: 3971378
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.
    Ehlken H; Schadendorf D; Eichmüller S
    Int J Cancer; 2004 Jan; 108(2):307-13. PubMed ID: 14639620
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Human melanoma-associated antigens: analysis of antigenic heterogeneity by molecular, serologic and flow-cytometric approaches.
    Morgan AC; Woodhouse C; Bartholemew R; Schroff R
    Mol Immunol; 1986 Feb; 23(2):193-200. PubMed ID: 2422545
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cell surface antigens of human uveal melanoma identified by monoclonal antibodies.
    Kalafut F; Kusenda J; Novotná L; Cernák A
    Czech Med; 1988; 11(2):73-80. PubMed ID: 3137006
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Heterogeneity of biologic responses of melanoma-specific CTL.
    Fonteneau JF; Le Dréan E; Le Guiner S; Gervois N; Diez E; Jotereau F
    J Immunol; 1997 Sep; 159(6):2831-9. PubMed ID: 9300706
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytes.
    Gervois N; Heuze F; Diez E; Jotereau F
    Hum Immunol; 1990 Jun; 28(2):112-8. PubMed ID: 2141008
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma.
    Kocan P; Jurkovic I; Böör A; Dudríková K; Krajcár R; Benický M; Kromydaki A
    Cesk Patol; 2004 Apr; 40(2):50-6. PubMed ID: 15233017
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
    Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
    Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Immunological aspects in malignant melanoma].
    Macher E
    Arch Dermatol Forsch; 1972; 244():234-9. PubMed ID: 4675197
    [No Abstract]   [Full Text] [Related]  

  • 75. Identification of a melanoma progression antigen as integrin VLA-2.
    Klein CE; Steinmayer T; Kaufmann D; Weber L; Bröcker EB
    J Invest Dermatol; 1991 Feb; 96(2):281-4. PubMed ID: 1991990
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin.
    Mortarini R; Gismondi A; Santoni A; Parmiani G; Anichini A
    Cancer Res; 1992 Aug; 52(16):4499-506. PubMed ID: 1386557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monoclonal antibodies to human melanoma-associated antigens: an amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody, and immune complexes.
    Morgan AC; McIntyre RF
    Cancer Res; 1983 Jul; 43(7):3155-9. PubMed ID: 6850625
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Immunological analysis of melanoma specific antigen. (I). In-vitro induction of melanoma-antigen specific killer T lymphocytes in primary immune response].
    Wakabayashi S; Taniguchi M; Tomioka H; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1983 Dec; 93(14):1469-76. PubMed ID: 6676498
    [No Abstract]   [Full Text] [Related]  

  • 79. Isolation and characterization of a heterodimeric surface antigen on human melanoma cells and evidence that it is the 4F2 cell activation/proliferation molecule.
    Dixon WT; Sikora LK; Demetrick DJ; Jerry LM
    Int J Cancer; 1990 Jan; 45(1):59-68. PubMed ID: 2404879
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Heterogeneity of T-cell clones infiltrating primary malignant melanomas.
    Yazdi AS; Morstedt K; Puchta U; Ghoreschi K; Flaig MJ; Rocken M; Sander CA
    J Invest Dermatol; 2006 Feb; 126(2):393-8. PubMed ID: 16374454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.